ROCALTROL

Rocaltrol Adverse Events Reported to the FDA Over Time

How are Rocaltrol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Rocaltrol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Rocaltrol is flagged as the suspect drug causing the adverse event.

Most Common Rocaltrol Adverse Events Reported to the FDA

What are the most common Rocaltrol adverse events reported to the FDA?

Hypercalcaemia	57 (6.42%)
Drug Ineffective	14 (1.58%)
Renal Failure	14 (1.58%)
Renal Failure Acute	14 (1.58%)
Drug Interaction	13 (1.46%)
Aspartate Aminotransferase Increase...	11 (1.24%)
Decreased Appetite	10 (1.13%)
Renal Impairment	10 (1.13%)
Blood Creatinine Increased	9 (1.01%)
Blood Parathyroid Hormone Increased	9 (1.01%)
Death	9 (1.01%)
	Show More
Pruritus	9 (1.01%)
Anaemia	8 (.9%)
Condition Aggravated	8 (.9%)
Hypocalcaemia	8 (.9%)
Hypotension	8 (.9%)
Coma	7 (.79%)
Diarrhoea	7 (.79%)
Hepatic Function Abnormal	7 (.79%)
Nausea	7 (.79%)
Rash Morbilliform	7 (.79%)
Altered State Of Consciousness	6 (.68%)
Anaphylactic Shock	6 (.68%)
Blood Urea Increased	6 (.68%)
Cardiac Failure	6 (.68%)
Gamma-glutamyltransferase Increased	6 (.68%)
Hypophagia	6 (.68%)
Muscle Spasms	6 (.68%)
Pain	6 (.68%)
Alanine Aminotransferase Increased	5 (.56%)
Angina Pectoris	5 (.56%)
Anorexia	5 (.56%)
Arthralgia	5 (.56%)
Blood Phosphorus Increased	5 (.56%)
Eosinophilia	5 (.56%)
Heart Rate Decreased	5 (.56%)
Hyperparathyroidism	5 (.56%)
Inflammation	5 (.56%)
Lenticular Opacities	5 (.56%)
Malaise	5 (.56%)
Myalgia	5 (.56%)
Pneumonia	5 (.56%)
Rectal Haemorrhage	5 (.56%)
Transient Ischaemic Attack	5 (.56%)
Abdominal Pain	4 (.45%)
Atrial Fibrillation	4 (.45%)
Blood Creatine Increased	4 (.45%)
Convulsion	4 (.45%)
Dehydration	4 (.45%)
Dialysis	4 (.45%)
Dyspepsia	4 (.45%)
Dysphagia	4 (.45%)
Fall	4 (.45%)
Hypereosinophilic Syndrome	4 (.45%)
International Normalised Ratio Incr...	4 (.45%)
Pancreatitis	4 (.45%)
Parapsoriasis	4 (.45%)
Platelet Count Decreased	4 (.45%)
Pruritus Generalised	4 (.45%)
Rash	4 (.45%)
Somnolence	4 (.45%)
Vomiting	4 (.45%)
White Blood Cell Count Decreased	4 (.45%)
White Blood Cell Count Increased	4 (.45%)
Abasia	3 (.34%)
Anaphylactic Reaction	3 (.34%)
Anuria	3 (.34%)
Aphagia	3 (.34%)
Asthenia	3 (.34%)
Blood Glucose Increased	3 (.34%)
Bone Pain	3 (.34%)
Cerebral Infarction	3 (.34%)
Cerebrovascular Accident	3 (.34%)
Confusional State	3 (.34%)
Disorientation	3 (.34%)
Dizziness	3 (.34%)
Drug Exposure During Pregnancy	3 (.34%)
Ear Pruritus	3 (.34%)
Erythema	3 (.34%)
Erythema Multiforme	3 (.34%)
Fluid Intake Reduced	3 (.34%)
Gait Disturbance	3 (.34%)
Hyperphosphataemia	3 (.34%)
Hypoglycaemia	3 (.34%)
Hypovitaminosis	3 (.34%)
Jaundice	3 (.34%)
Jugular Vein Thrombosis	3 (.34%)
Labyrinthitis	3 (.34%)
Lactose Intolerance	3 (.34%)
Leukopenia	3 (.34%)
Liver Disorder	3 (.34%)
Long Qt Syndrome	3 (.34%)
Lung Disorder	3 (.34%)
Malnutrition	3 (.34%)
Metabolic Acidosis	3 (.34%)
Multiple Fractures	3 (.34%)
Muscular Weakness	3 (.34%)
Nephrolithiasis	3 (.34%)
Nephropathy Toxic	3 (.34%)
Oliguria	3 (.34%)
Osteonecrosis	3 (.34%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Rocaltrol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Rocaltrol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Rocaltrol

What are the most common Rocaltrol adverse events reported to the FDA?

Bone, Calcium, Magnesium And Phosph...	68 (7.66%)
Renal Disorders	51 (5.74%)
Epidermal And Dermal Conditions	44 (4.95%)
Neurological	34 (3.83%)
Therapeutic And Nontherapeutic Effe...	32 (3.6%)
Gastrointestinal Signs	31 (3.49%)
Hematology Investigations	26 (2.93%)
Appetite And General Nutritional	24 (2.7%)
Hepatobiliary	22 (2.48%)
Renal And Urinary Tract Investigati...	22 (2.48%)
Hepatic And Hepatobiliary	17 (1.91%)
	Show More
Infections - Pathogen Unspecified	17 (1.91%)
Respiratory	15 (1.69%)
White Blood Cell	15 (1.69%)
Muscle	14 (1.58%)
Cardiac Arrhythmias	13 (1.46%)
Endocrine Investigations	13 (1.46%)
Bone And Joint Injuries	12 (1.35%)
Allergic Conditions	11 (1.24%)
Anemias Nonhemolytic And Marrow Dep...	11 (1.24%)
Central Nervous System Vascular	11 (1.24%)
Injuries	11 (1.24%)
Bone Disorders	10 (1.13%)
Decreased And Nonspecific Blood Pre...	10 (1.13%)
Water, Electrolyte And Mineral	10 (1.13%)
Cardiac And Vascular Investigations	9 (1.01%)
Fatal Outcomes	9 (1.01%)
Deliria	8 (.9%)
Electrolyte And Fluid Balance Condi...	8 (.9%)
Embolism And Thrombosis	8 (.9%)
Gastrointestinal Motility And Defec...	8 (.9%)
Heart Failures	8 (.9%)
Acid-base	7 (.79%)
Anterior Eye Structural Change, Dep...	7 (.79%)
Gastrointestinal Hemorrhages	7 (.79%)
Joint	7 (.79%)
Procedural And Device Related Injur...	7 (.79%)
Chemical Injury And Poisoning	6 (.68%)
Glucose Metabolism Disorders	6 (.68%)
Metabolic, Nutritional And Blood Ga...	6 (.68%)
Oral Soft Tissue Conditions	6 (.68%)
Coronary Artery	5 (.56%)
Hematological And Lymphoid Tissue T...	5 (.56%)
Medication Errors	5 (.56%)
Microbiology And Serology	5 (.56%)
Nephropathies	5 (.56%)
Parathyroid Gland	5 (.56%)
Physical Examination Topics	5 (.56%)
Urolithiases	5 (.56%)
Coagulopathies And Bleeding Diathes...	4 (.45%)
Exocrine Pancreas Conditions	4 (.45%)
Lower Respiratory Tract Disorders	4 (.45%)
Protein And Chemistry Analyses	4 (.45%)
Seizures	4 (.45%)
Urinary Tract Signs	4 (.45%)
Anxiety Disorders	3 (.34%)
Aural	3 (.34%)
Body Temperature Conditions	3 (.34%)
Food Intolerance Syndromes	3 (.34%)
Inner Ear And Viiith Cranial Nerve	3 (.34%)
Investigations, Imaging And Histopa...	3 (.34%)
Movement Disorders	3 (.34%)
Obstetric And Gynecological Therape...	3 (.34%)
Product Quality Issues	3 (.34%)
Renal And Urinary Tract Therapeutic...	3 (.34%)
Vitamin Related	3 (.34%)
Bacterial Infectious	2 (.23%)
Bile Duct	2 (.23%)
Cognitive And Attention Disorders	2 (.23%)
Disturbances In Thinking	2 (.23%)
Enzyme	2 (.23%)
Eye	2 (.23%)
Gastrointestinal Conditions	2 (.23%)
Gastrointestinal Inflammatory Condi...	2 (.23%)
Miscellaneous And Site Unspecified ...	2 (.23%)
Myocardial	2 (.23%)
Neonatal And Perinatal Conditions	2 (.23%)
Ocular Neuromuscular	2 (.23%)
Pleural	2 (.23%)
Pregnancy, Labour, Delivery And Pos...	2 (.23%)
Respiratory Disorders Congenital	2 (.23%)
Salivary Gland Conditions	2 (.23%)
Sexual Function And Fertility	2 (.23%)
Therapeutic Procedures And Supporti...	2 (.23%)
Thyroid Gland	2 (.23%)
Vascular	2 (.23%)
Vascular Hypertensive	2 (.23%)
Viral Infectious	2 (.23%)
Abortions And Stillbirth	1 (.11%)
Breast	1 (.11%)
Bronchial Disorders	1 (.11%)
Cardiac Disorder Signs	1 (.11%)
Cardiac Valve	1 (.11%)
Congenital And Hereditary	1 (.11%)
Eating Disorders	1 (.11%)
Endocrine Gland Therapeutic Procedu...	1 (.11%)
Fractures	1 (.11%)
Gallbladder	1 (.11%)
Gastrointestinal Neoplasms Malignan...	1 (.11%)
Gastrointestinal Therapeutic Proced...	1 (.11%)
Gastrointestinal Ulceration And Per...	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Rocaltrol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Rocaltrol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.